News Flash: Analysts Just Made A Sizeable Upgrade To Their Compugen Ltd. (NASDAQ:CGEN) Forecasts
News Flash: Analysts Just Made A Sizeable Upgrade To Their Compugen Ltd. (NASDAQ:CGEN) Forecasts
Compugen Ltd. (NASDAQ:CGEN) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with analysts modelling a real improvement in business performance.
Compugen医疗股份有限公司(NASDAQ: CGEN)的股东今日有理由微笑,分析师对今年的财务预测做出了实质性的升级。共识估计表明投资者可以期待大幅增加的实质收入和每股收益,分析师模拟实际业务表现的真正改善。
Following the upgrade, the current consensus from Compugen's dual analysts is for revenues of US$45m in 2024 which - if met - would reflect a reasonable 5.0% increase on its sales over the past 12 months. The losses are expected to disappear over the next year or so, with forecasts for a profit of US$0.04 per share this year. Yet before this consensus update, the analysts had been forecasting revenues of US$37m and losses of US$0.05 per share in 2024. So we can see that this has sparked a pretty clear upgrade to expectations, with higher revenues anticipated to lead to profit sooner than previously forecast.
升级后,Compugen医疗股份有限公司的双重分析师当前的共识是2024年的收入为4500万美元,如果实现将反映出过去12个月销售额合理的5.0%增长。预期亏损将在明年左右消失,预测今年每股收益为0.04美元。然而,在这一共识更新之前,分析师预测2024年收入为3700万美元,每股亏损为0.05美元。因此,我们可以看到,这已经引发了对预期的明显升级,预计更高的收入将比先前预测的更快地带来利润。
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's pretty clear that there is an expectation that Compugen's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 10% growth on an annualised basis. This is compared to a historical growth rate of 66% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 18% annually. Factoring in the forecast slowdown in growth, it seems obvious that Compugen is also expected to grow slower than other industry participants.
现在看看更大的画面,我们可以通过看看它们与过去的业绩和行业增长预测相比如何来理解这些预测的方式之一。很明显,Compugen医疗股份有限公司的收入增长预计将大幅放缓,预计2024年底的收入年平均增长率为10%。这与过去五年的历史增长率66%相比。将其与该行业中其他公司(分析师预测)的预期收入增长18%的预期相比,考虑到预期的增长放缓,很明显,Compugen医疗股份有限公司也预计比其他行业参与者增长较慢。
The Bottom Line
最重要的事情是分析师增加了它对下一年每股亏损的估计。令人欣慰的是,营收预测未发生重大变化,业务仍有望比整个行业增长更快。共识价格目标稳定在28.50美元,最新估计不足以对价格目标产生影响。
The most important thing to take away from this upgrade is that the consensus now expects Compugen to become profitable this year. Fortunately, they also upgraded their revenue estimates, and are forecasting revenues to grow slower than the wider market. The clear improvement in sentiment should be enough to get most shareholders feeling more optimistic about Compugen's future.
这次升级最重要的是共识现在预计Compugen医疗股份有限公司将在今年实现盈利。幸运的是,他们还提高了收入预期,并预测收入增长速度将慢于更广泛的市场。情绪明显改善足以让大多数股东对Compugen医疗股份有限公司的未来感到更加乐观。
Still, the long-term prospects of the business are much more relevant than next year's earnings. At least one analyst has provided forecasts out to 2026, which can be seen for free on our platform here.
然而,企业的长期前景比明年的收益更具有参考价值。至少有一位分析师提供了到2026年的预测,在此处免费查看。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks with high insider ownership.
当然,看到公司高管将大量资金投入股票与分析师是否升级他们的估计同样有用。因此,您可能还希望搜索此高内部持股的股票免费名单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。